The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts
The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts
分析師意見：17位專家眼中的愛德華生命科學
An in-depth analysis...Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
17位分析師提供的分析師對愛德華茲生命科學（紐約證券交易所代碼：EW）在上個季度的評級從看漲到看跌不等。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表簡要概述了分析師最近的評級，提供了對過去30天情緒變化的見解，並與前幾個月進行了比較以獲得整體視角。
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $73.71, a high estimate of $90.00, and a low estimate of $63.00. This current average represents a 7.72% decrease from the previous average price target of $79.88.
分析師已經爲愛德華茲生命科學設定了12個月的目標股價，顯示平均目標股價爲73.71美元，最高估計爲90.00美元，低估值爲63.00美元。目前的平均價格比之前的平均目標價79.88美元下降了7.72％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
An in-depth analysis...
對分析師...
登入免費觀看全文
登入/註冊
熱門討論
特斯拉績後巨震，後市你怎麽看？
特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
Moo Earnings
01/24 10:26
TSLA收益預覽：猜測開盤價贏取獎勵！